Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0001415889-25-007286 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-06 | 2025-03-04 | ELVN | Hohl Benjamin | CFO | M - OptEx | $2.48 | +10.0K | 23.0K | +77% | +$24.8K |
| D | 2025-03-06 | 2025-03-04 | ELVN | Hohl Benjamin | CFO | M - OptEx | $0.00 | -10.0K | 132.8K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | M | A | 10,000 | $2.48 | 23,000 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2025-03-04 | M | D | 10,000 | $0.00 | 132,806 | D | $2.48 · — to 2031-08-02 | 10,000 Common Stock | (F1) The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. |